You can buy or sell MacroGenics and other stocks, options, ETFs, and crypto commission-free!
MacroGenics, Inc. Common Stock, also called MacroGenics, is a clinical-stage biopharmaceutical company, which engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. Read More 2. Its product pipeline includes Margetuximab, Flotetuzumab, Enoblituzumab, MGA012, MGD013, MGD019, MGD009, MGC018, and MGD007 for oncology; and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.
52 Week High
52 Week Low
Seeking AlphaMay 15
MacroGenics +13.1% on new data from breast cancer study
MacroGenics (NASDAQ:MGNX) is up 13.1% in postmarket trading after the company revealed positive data from its late-stage study of a cancer drug.
Expected Aug 6, After Hours